| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.00▲ | 8.99▲ | 8.98▲ | 9.22▼ | 8.81▲ |
| MA10 | 9.01▲ | 9.00▲ | 9.04▼ | 9.09▼ | 8.66▲ |
| MA20 | 8.99▲ | 9.03▲ | 9.13▼ | 8.91▲ | 7.81▲ |
| MA50 | 9.02▲ | 9.26▼ | 9.15▼ | 8.66▲ | 7.71▲ |
| MA100 | 9.23▼ | 9.12▼ | 8.97▲ | 7.64▲ | 7.20▲ |
| MA200 | 9.18▼ | 8.93▲ | 8.80▲ | 7.40▲ | 8.98▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | 0.007▲ | -0.021▼ | 0.003▲ | 0.134▲ |
| RSI | 52.249▲ | 46.344▼ | 45.533▼ | 53.364▲ | 63.983▲ |
| STOCH | 50.537 | 36.069 | 34.615 | 58.807 | 67.733 |
| WILL %R | -12.500▲ | -57.692 | -53.571 | -50.595 | -24.927▲ |
| CCI | 93.621 | -10.715 | -20.813 | 19.890 | 137.404▲ |
| CDL | $NVCT Matching Low Candlestick Pattern Detected | Set Alert |
|
Tuesday, February 10, 2026 11:30 PM
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...
|
|
Wednesday, December 17, 2025 07:06 AM
Resistance remains one of the biggest unsolved problems in modern cancer treatment, and nowhere is that more evident than in lung cancer. AstraZeneca’s Tagrisso has become the gold standard for ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/03/26 | 9.10 | 9.19 | 8.90 | 9.03 | 30,400 |
| 12/03/26 | 9.16 | 9.195 | 8.925 | 9.02 | 41,809 |
| 11/03/26 | 9.54 | 9.6537 | 9.21 | 9.33 | 39,289 |
| 10/03/26 | 9.07 | 9.88 | 9.07 | 9.65 | 94,136 |
| 09/03/26 | 8.88 | 9.14 | 8.72 | 9.08 | 44,488 |
| 06/03/26 | 8.91 | 9.28 | 8.84 | 8.96 | 80,157 |
| 05/03/26 | 8.93 | 9.125 | 8.915 | 9.04 | 58,852 |
| 04/03/26 | 8.86 | 9.16 | 8.7017 | 9.03 | 58,944 |
| 03/03/26 | 8.89 | 8.98 | 8.6288 | 8.71 | 42,128 |
| 02/03/26 | 8.71 | 9.10 | 8.6845 | 9.04 | 45,413 |
|
|
||||
|
|
||||
|
|